Minimal Residual Disease (MRD) Assessment By Multiparametric Flow Cytometry Is Prognostic for Progression-Free Survival in Phase 1/1b Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients Treated with Idasanutlin MDM2 Antagonist
Publication/Presentation Date
12-2016
Volume
128
Issue
22
First Page
2843
Last Page
2843
Published In/Presented At
Disciplines
Medicine and Health Sciences
Department(s)
Hematology-Medical Oncology Division
Document Type
Article
COinS